Clofarabine in pediatric acute leukemia: Current findings and issues

Nobuko Hijiya, Elly Barry, Robert J. Arceci

Research output: Contribution to journalArticle

Abstract

Clofarabine is a second-generation purine nucleoside analog and has significant anti-leukemic activity as a single agent. It is approved by the United States Food and Drug Administration (FDA) for the treatment of relapsed or refractory acute lymphoblastic leukemia (ALL) in children. Combinations of clofarabine with purine nucleoside analogs or DNA-damaging agents have been investigated utilizing synergistic effects and now tested in a number of studies including a frontline study. In this article, we review the development of clofarabine, rationale and history of combination regimens, and their potential roles and toxicities in the treatment of pediatric ALL that are important to treating clinicians.

Original languageEnglish (US)
Pages (from-to)417-422
Number of pages6
JournalPediatric Blood and Cancer
Volume59
Issue number3
DOIs
StatePublished - Sep 2012

Fingerprint

Purine Nucleosides
Leukemia
Pediatrics
Precursor Cell Lymphoblastic Leukemia-Lymphoma
United States Food and Drug Administration
DNA
Therapeutics
clofarabine

Keywords

  • ALL
  • Clofarabine
  • New agent
  • Relapse

ASJC Scopus subject areas

  • Oncology
  • Pediatrics, Perinatology, and Child Health
  • Hematology

Cite this

Clofarabine in pediatric acute leukemia : Current findings and issues. / Hijiya, Nobuko; Barry, Elly; Arceci, Robert J.

In: Pediatric Blood and Cancer, Vol. 59, No. 3, 09.2012, p. 417-422.

Research output: Contribution to journalArticle

Hijiya, Nobuko ; Barry, Elly ; Arceci, Robert J. / Clofarabine in pediatric acute leukemia : Current findings and issues. In: Pediatric Blood and Cancer. 2012 ; Vol. 59, No. 3. pp. 417-422.
@article{d1bf2cb2227547b982aee12f6274ed84,
title = "Clofarabine in pediatric acute leukemia: Current findings and issues",
abstract = "Clofarabine is a second-generation purine nucleoside analog and has significant anti-leukemic activity as a single agent. It is approved by the United States Food and Drug Administration (FDA) for the treatment of relapsed or refractory acute lymphoblastic leukemia (ALL) in children. Combinations of clofarabine with purine nucleoside analogs or DNA-damaging agents have been investigated utilizing synergistic effects and now tested in a number of studies including a frontline study. In this article, we review the development of clofarabine, rationale and history of combination regimens, and their potential roles and toxicities in the treatment of pediatric ALL that are important to treating clinicians.",
keywords = "ALL, Clofarabine, New agent, Relapse",
author = "Nobuko Hijiya and Elly Barry and Arceci, {Robert J.}",
year = "2012",
month = "9",
doi = "10.1002/pbc.24112",
language = "English (US)",
volume = "59",
pages = "417--422",
journal = "Pediatric Blood and Cancer",
issn = "1545-5009",
publisher = "Wiley-Liss Inc.",
number = "3",

}

TY - JOUR

T1 - Clofarabine in pediatric acute leukemia

T2 - Current findings and issues

AU - Hijiya, Nobuko

AU - Barry, Elly

AU - Arceci, Robert J.

PY - 2012/9

Y1 - 2012/9

N2 - Clofarabine is a second-generation purine nucleoside analog and has significant anti-leukemic activity as a single agent. It is approved by the United States Food and Drug Administration (FDA) for the treatment of relapsed or refractory acute lymphoblastic leukemia (ALL) in children. Combinations of clofarabine with purine nucleoside analogs or DNA-damaging agents have been investigated utilizing synergistic effects and now tested in a number of studies including a frontline study. In this article, we review the development of clofarabine, rationale and history of combination regimens, and their potential roles and toxicities in the treatment of pediatric ALL that are important to treating clinicians.

AB - Clofarabine is a second-generation purine nucleoside analog and has significant anti-leukemic activity as a single agent. It is approved by the United States Food and Drug Administration (FDA) for the treatment of relapsed or refractory acute lymphoblastic leukemia (ALL) in children. Combinations of clofarabine with purine nucleoside analogs or DNA-damaging agents have been investigated utilizing synergistic effects and now tested in a number of studies including a frontline study. In this article, we review the development of clofarabine, rationale and history of combination regimens, and their potential roles and toxicities in the treatment of pediatric ALL that are important to treating clinicians.

KW - ALL

KW - Clofarabine

KW - New agent

KW - Relapse

UR - http://www.scopus.com/inward/record.url?scp=84861726534&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84861726534&partnerID=8YFLogxK

U2 - 10.1002/pbc.24112

DO - 10.1002/pbc.24112

M3 - Article

C2 - 22354543

AN - SCOPUS:84861726534

VL - 59

SP - 417

EP - 422

JO - Pediatric Blood and Cancer

JF - Pediatric Blood and Cancer

SN - 1545-5009

IS - 3

ER -